Form 4: Silexion CFO Granted 49,726 Ordinary Shares

Silexion Therapeutics Corp's CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 49,726 ordinary shares as compensation.

Summary

• Hadar Mirit Horenshtein, the Chief Financial Officer and Secretary of Silexion Therapeutics Corp (SLXN), acquired 49,726 ordinary shares.
• The transaction occurred on February 20, 2026, at a price of $0 per share.
• This acquisition represents a grant of fully vested restricted share units (RSUs) that were immediately settled for underlying ordinary shares, approved by the Issuer's board of directors.
• Following this transaction, Hadar Mirit Horenshtein beneficially owns a total of 50,146 ordinary shares.
• The reported number of ordinary shares reflects adjustments due to previous 1-for-9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024, and July 29, 2025, respectively.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management's interests with shareholder value, without indicating any immediate operational changes.

Positives

• The grant of fully vested restricted share units to a key executive like the CFO indicates continued commitment and aligns management's interests with long-term shareholder value.
• Board approval of the grant suggests confidence in the executive's performance and future contributions to the company.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Issuer's board of directors approved the grant of fully vested restricted share units to the reporting person.

Industry Context

StockSavvy.ai notes that executive stock grants are a common practice across industries to incentivize leadership and align their interests with long-term shareholder value. The specific details of the grant, such as immediate vesting, often reflect company-specific compensation strategies aimed at retaining key talent.

Comparison to Industry Standards

• Executive compensation through equity grants is a standard practice in publicly traded companies, particularly in the biotechnology or pharmaceutical sectors where long-term value creation is paramount.
• While specific grant sizes vary based on company size, executive role, and performance metrics, the immediate vesting of RSUs for service is a common method for retaining key talent.
• For example, similar grants are observed at companies like BioNTech or Moderna for their executive teams, though the scale and specific terms would differ based on market capitalization and strategic objectives.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant to an officer of the company (Hadar Mirit Horenshtein), which constitutes a related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial interests with the company's performance, potentially fostering long-term value creation.
• Management: The CFO receives additional equity compensation, reinforcing her stake in the company's success.

Key Dates

Recommendation

This Form 4 filing details a standard executive compensation grant and does not provide new information that would fundamentally alter the investment thesis for Silexion Therapeutics Corp. Investors should consider this a routine disclosure rather than a catalyst for a 'buy' or 'sell' decision.

Keywords

Silexion Therapeutics, SLXN, Form 4, Insider Transaction, Stock Grant, Restricted Share Units, RSU, Executive Compensation, Hadar Mirit Horenshtein, CFO